14th Mar 2022 14:14
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Publishes research expanding on analysis of a gene mutation in an interferon receptor that is linked to corticosteroid response and outcomes in acute respiratory distress syndrome and Covid-19 patients. Builds on Faron's findings from its phase III 'Interest' trial for Traumakine in ARDS patients. Traumakine is an investigational intravenous interferon beta-1a therapy. Read More
